Home » Newsletters » BioWorld Science

BioWorld Science

May 9, 2013

View Archived Issues

Soluble CD163 levels strongly correlate with disease severity and outcome in ALF

Both mU1 and XL-784 show efficacy in preventing atherosclerosis progression in vivo

Novel fatty acid synthase inhibitor GSK-2194069 shows activity in animal models of prostate cancer

Drug for asthma may have clinical application to treat obesity

Phase III data for brinzolamide/brimonidine combination reported

DBV Technologies and Mount Sinai Hospital form food allergy partnership

Endocyte's oncolytic agent EC-1169 specifically targets PSMA

Ono and Dainippon Sumitomo set to expand limaprost alfadex business to China

SymBio commences phase II Japanese trial of Treakisym in CLL

PharmaMar completes enrollment for phase IIb trial in resistant/refractory ovarian cancer

Agensys identifies novel target for bladder cancer and develops antibody-drug conjugate

Merck & Co. updates development activities of first quarter 2013

Pfizer reviews development highlights of first quarter 2013

Astellas presents a novel immunosuppressive compound with promising in vivo activity

Takeda enters agreement to acquire Inviragen

Primary endpoint met in phase III panitumumab trial in metastatic colorectal cancer

Sage Therapeutics designs new GABA(A) receptor modulators

Cell encapsulation technology shows efficacy against mammary tumors in dogs

Cell Medica treats first pediatric patient in early-stage trial of Cytovir ADV

FDA accepts Merck & Co.'s BLA for ragweed pollen allergy tablet

FDA approves EXCELLA III trial of DESyne stent system

Seattle Genetics and Spirogen prepare novel pyrrolobenzodiazepines

Chinese researchers present novel fusion proteins for cancer

Novel mTOR and PI3K inhibitors reported by Jiangsu Hengrui Medicine

French group patents new murine MAbs

FDA grants orphan drug designation to Jennerex's Pexa-Vec for hepatocellular carcinoma